特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
961504

血友病の世界市場 (治療レジメン別、種類別、治療法別):考察・予測、新型コロナウイルス感染症 (COVID-19) の潜在的影響 (2020~2024年)

Global Hemophilia Market (By Treatment Regimen, Type & Therapy): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)

出版日: | 発行: Koncept Analytics | ページ情報: 英文 131 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
血友病の世界市場 (治療レジメン別、種類別、治療法別):考察・予測、新型コロナウイルス感染症 (COVID-19) の潜在的影響 (2020~2024年)
出版日: 2020年09月21日
発行: Koncept Analytics
ページ情報: 英文 131 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の血友病市場は、2020~2024年に5.61%のCAGRで成長し、2024年に138億6000万米ドルに達すると予想されています。医療費の増大や特定血友病の患者数の増加などが市場の成長を促進する一方、治療費の高さや治療法の切り替えへの抵抗感といった課題に直面することが考えられます。治療レジメン別に見ると、予防療法の方がシェアが高く、対処療法 (オンデマンド) がそれに続いています。治療法の種類別では、補充療法が大きなシェアを占めています。

当レポートでは、世界の血友病市場について分析し、疾患の概要や主な診断・治療法、世界全体の市場規模 - 患者数、治療薬の売上高 - の動向見通し (種類別、重症度別、治療の種類別、治療レジメン別)、地域別の詳細動向、主な市場促進・抑制要因、主要企業のプロファイルなどを調査しております。

目次

第1章 市場概要

  • 血友病
  • 血友病の種類
  • 兆候と症状
  • 血友病の診断
  • 血友病の治療

第2章 新型コロナウイルス感染症 (COVID-19) の影響

  • 世界経済への影響
  • 世界のCOVID-19有病者数
  • 医療費への影響

第3章 世界市場の分析

  • 世界の血友病の市場規模 (金額ベース)
  • 世界の血友病の市場規模、予測値 (金額ベース)
  • 世界の血友病市場:治療レジメン別
  • 世界の血友病市場:種類別
    • 血友病Aの市場規模、予測値 (金額ベース)
    • 血友病A市場:重症度別
    • 血友病A市場:治療法の種類別
    • 血友病A市場:治療レジメン別
    • 血友病Aの市場規模、予測値:治療レジメン別 (金額ベース)
    • 血友病Bの市場規模、予測値 (金額ベース)
    • 血友病B市場:重症度別
    • 血友病B市場:治療法の種類別
    • 血友病B市場:治療レジメン別
    • 血友病Bの市場規模、予測値:治療レジメン別 (金額ベース)
  • 世界の血友病市場:治療法別
    • 補充療法:市場規模、予測値 (金額ベース)
    • 免疫寛容導入 (ITI) 療法:市場規模、予測値 (金額ベース)
  • 世界の血友病市場:地域別

第4章 地域市場分析

  • 北米
    • 血友病の市場規模 (金額ベース)
    • 血友病の市場規模、予測値 (金額ベース)
    • 米国
      • 市場規模 (金額ベース)
      • 市場規模、予測値 (金額ベース)
      • 市場規模:種類別 (金額ベース)
      • 市場規模、予測値:種類別 (金額ベース)
      • 血友病A市場 - 治療済み患者数、予測値
      • 血友病A市場 - 予防治療中の重症患者数
      • 血友病A市場 - 対処療法中の重症患者数
      • 血友病A市場 - 予防治療中の軽症・中症患者数
      • 血友病A市場 - 対処療法中の軽症・中症患者数
      • 血友病B市場 - 治療済み患者数、予測値
      • 血友病B市場 - 予防治療中の重症患者数
      • 血友病B市場 - 対処療法中の重症患者数
      • 血友病B市場 - 予防治療中の軽症・中症患者数
      • 血友病B市場 - 対処対処療中の軽症・中症患者数
  • 欧州
    • 血友病の市場規模 (金額ベース)
    • 血友病の市場規模、予測値 (金額ベース)
    • 血友病の患者数、予測値
    • 血友病Aの患者数、予測値
    • 血友病Bの患者数、予測値
  • アジア太平洋
    • 血友病の市場規模 (金額ベース)
    • 血友病の市場規模、予測値 (金額ベース)
  • 他の国々 (RoW)
    • 血友病の市場規模 (金額ベース)
    • 血友病の市場規模、予測値 (金額ベース)

第5章 市場力学

  • 成長促進要因
    • 予防的治療への関心の増大
    • 診断率の向上
    • 世界の医療費の増加
  • 主な傾向と動静
    • 半減期延長型製剤への関心の移行
    • 新たな血友病治療薬の開発
    • 遺伝子治療の人気
  • 課題
    • 高額の治療費
    • 新しい治療法への切り替えへの消極的姿勢

第6章 競合情勢

  • 世界の市場
    • 市場収益額の比較:主要企業間
    • 株式時価総額の比較:主要企業間
    • 研究開発費の比較:主要企業間
    • 世界の血友病市場のシェア構造
    • 世界の血友病A第VIII因子製品の市場シェア:企業別
    • 世界の血友病A第VIII因子遺伝子治療の市場シェア、予測値
    • 世界の血友病B市場シェア:企業別
    • 世界の血友病B第IX因子製品の市場シェア、予測値
    • 世界の血友病B第IX因子遺伝子治療の市場シェア、予測値
    • 主要企業:主な抗血友病製品
  • 米国市場
    • 米国の血友病Aの市場シェア:企業別
  • 欧州市場
    • 欧州の血友病Aの市場シェア:企業別

第7章 企業プロファイル

  • Pfizer Inc.
  • Bayer Group
  • Sanofi S.A.
  • 武田薬品工業
  • Novo Nordisk
  • CSL Limited
図表

List of Charts

  • Types of Hemophilia
  • Diagnosis of Hemophilia
  • Global Coronavirus Prevalence (Jan'20 - Sep'20)
  • Global Hemophilia Market by Value (2015-2019)
  • Global Hemophilia Market Forecast by Value (2020-2024)
  • Global Hemophilia Market by Treatment Regimen (2019)
  • Global Hemophilia Market by Type (2019)
  • Global Hemophilia A Market Forecast by Value (2019-2024)
  • Global Hemophilia A Market by Severity (2019)
  • Global Hemophilia A Market by Treatment Type (2019)
  • Global Hemophilia A Market by Treatment Regimen (2019 & 2024)
  • Global Hemophilia A Market Value by Treatment Regimen (2019-2024)
  • Global Hemophilia B Market Forecast by Value (2019-2024)
  • Global Hemophilia B Market by Severity (2019)
  • Global Hemophilia B Market by Treatment Type (2019)
  • Global Hemophilia B Market by Treatment Regimen (2019 & 2024)
  • Global Hemophilia B Market Value by Treatment Regimen (2019-2024)
  • Global Hemophilia Market by Therapy (2019)
  • Global Hemophilia Replacement Therapy Market Forecast by Value (2019-2024)
  • Global Hemophilia ITI Therapy Market Forecast by Value (2019-2024)
  • Global Hemophilia Market by Region (2019)
  • North America Hemophilia Market by Value (2015-2019)
  • North America Hemophilia Market Forecast by Value (2020-2024)
  • The US Hemophilia Market by Value (2015-2019)
  • The US Hemophilia Market Forecast by Value (2020-2024)
  • The US Hemophilia Market by Type (2019)
  • The US Hemophilia A Market Forecast by Value (2019-2024)
  • The US Hemophilia A Treated Patient Volume Forecast (2019-2024)
  • The US Hemophilia A Severe Patients on Prophylactic Therapy (2019-2024)
  • The US Hemophilia A Severe Patients on On-Demand Therapy (2019-2024)
  • The US Hemophilia A Mild to Moderate Patients on Prophylaxis Therapy (2019-2023)
  • The US Hemophilia A Mild to Moderate Patients on On-Demand Therapy (2019-2024)
  • The US Hemophilia B Market Forecast by Value (2019-2024)
  • The US Hemophilia B Treated Patients Volume Forecast (2019-2024)
  • The US Hemophilia B Severe Patients on Prophylaxis Therapy (2019-2024)
  • The US Hemophilia B Severe Patients on On-Demand Therapy (2019-2024)
  • The US Hemophilia B Mild to Moderate Patients on Prophylaxis Therapy (2019-2024)
  • The US Hemophilia B Mild to Moderate Patients on On-Demand Therapy (2019-2024)
  • Europe Hemophilia Market by Value (2015-2019)
  • Europe Hemophilia Market Forecast by Value (2020-2024)
  • Europe Hemophilia Patient Volume Forecast (2019-2024)
  • Europe Hemophilia A Patient Volume Forecast (2019-2024)
  • Europe Hemophilia B Patient Volume Forecast (2019-2024)
  • Asia Pacific Hemophilia Market by Value (2015-2019)
  • Asia Pacific Hemophilia Market Forecast by Value (2020-2024)
  • ROW Hemophilia Market by Value (2015-2019)
  • ROW Hemophilia Market Forecast by Value (2020-2023)
  • Global Market Share of Hemophilia A and B Patients on Prophylaxis (2019)
  • Global Identified Hemophilia Patients Volume (2012-2019)
  • Global Healthcare Expenditure (2014-2018)
  • Global Hemophilia A Market Share by Company (2019)
  • Global Hemophilia A Factor VIII Products Market Share by Company (2023/2030)
  • Global Hemophilia A FVIII Gene Therapy Market Share Forecast (2030)
  • Global Hemophilia B Market Share by Company (2019)
  • Global Hemophilia B Factor IX Products Market Share Forecast (2023/2030)
  • Global Hemophilia B Factor IX Gene Therapy Market Share Forecast (2030)
  • The US Hemophilia A Market Share by Company (2019)
  • Europe Hemophilia B Market Share by Company (2019)
  • Pfizer Inc. Revenue and Net Income (2015-2019)
  • Pfizer Inc. Revenue by Segment (2019)
  • Pfizer Inc. Revenue by Region (2019)
  • Bayer Group Net Sales and Net Income (2014-2018)
  • Bayer Group Net Sales and Net Income (2014-2018)
  • Bayer Group Net Sales and Net Income (2014-2018)
  • Sanofi S.A. Net Sales and Net Income (2014-2018)
  • Sanofi S.A. Net Sales by Segment (2019)
  • Sanofi S.A. Net Sales by Region (2019)
  • Takeda Pharmaceutical Company Revenue and Net Income (2016-2020)
  • Takeda Pharmaceutical Company Revenue by Segment (2020)
  • Takeda Pharmaceutical Company Revenue by Region (2020)
  • Novo Nordisk Net Sales and Net Profit (2014-2018)
  • Novo Nordisk Net Sales by Segment (2019)
  • Novo Nordisk Net Sales by Region (2019)
  • CSL Limited Sales Revenue and Net Profit (2016-2020)
  • CSL Limited Sales Revenue by Segment (2020)
  • CSL Limited Sales Revenue by Region (2020)

List of Tables

  • Signs & Symptoms of Hemophilia
  • Extended Half Life Products (2019)
  • Development of New Novel Hemophilia Treatments (2019)
  • Hemophilia Gene Therapy Candidates (2018/2019)
  • Key Players - Revenue Comparison (2019/2020)
  • Key Players - Market Capitalization Comparison (2020)
  • Key Players - Research & Development Expenses Comparison (2019/2020)
  • Key Players - Main Anti-Hemophilia Products
目次

The global hemophilia market is anticipated to reach US$13.86 billion in 2024, growing at a CAGR of 5.61% during the period spanning 2020-2024. The growth in the market has been driven by factors like increasing healthcare expenditure and surging identified hemophilia patient volume. The market is expected to face certain challenges such as high cost of treatment and reluctance to switch to newer therapies. To overcome these challenges, the market would witness some key trends like development of novel hemophilia treatments and rising popularity of gene therapy.

The global hemophilia market by treatment regimen can be segmented as follows: prophylaxis and on-demand. In 2019, the higher share was held by prophylaxis segment, followed by on-demand segment. The global hemophilia market by type can be segmented into the following: hemophilia A and hemophilia B, where hemophilia A held a larger share of the market in 2019. The global hemophilia market by therapy can be segmented as follows: replacement therapy and ITI therapy. The dominant share of the market in 2019 was held by replacement therapy segment. The global hemophilia market by region can be segmented into the following regions: North America, Europe and Asia Pacific.

In 2019, the dominant share of the market was held by North America, followed by Europe and Asia Pacific. The factors like rising prevalence of hemophilia, growing knowledge amongst individuals regarding different treatment methods and surging inclination towards prophylaxis treatment contributed towards growth in the North American market.

Scope of the report:

  • The report provides a comprehensive analysis of the global hemophilia market, segmented into hemophilia A and hemophilia B.
  • The major regional markets North America, Europe and Asia Pacific with country analysis of the US have been analyzed.
  • The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
  • The competitive landscape of the market, along with the company profiles of leading players (Pfizer Inc., Bayer Group, Sanofi S.A., Takeda Pharmaceutical Company, Novo Nordisk and CSL Limited) are also presented in detail.

Key Target Audience:

  • Hemophilia Drugs Manufacturers
  • API Suppliers
  • End Users (Hospital, Medical centers, Clinical Institutes)
  • Healthcare Consulting Firms
  • Investment Banks
  • Government Bodies & Regulating Authorities

Table of Contents

1. Market Overview

  • 1.1 Hemophilia
  • 1.2 Types of Hemophilia
  • 1.3 Signs & Symptoms
  • 1.4 Diagnosis of Hemophilia
  • 1.5 Treatment of Hemophilia

2. Impact of COVID-19

  • 2.1 Impact on Global Economy
  • 2.2 Global Prevalence of COVID-19
  • 2.3 Impact on Healthcare Spending

3. Global Market Analysis

  • 3.1 Global Hemophilia Market by Value
  • 3.2 Global Hemophilia Market Forecast by Value
  • 3.3 Global Hemophilia Market by Treatment Regimen
  • 3.4 Global Hemophilia Market by Type
    • 3.4.1 Global Hemophilia A Market Forecast by Value
    • 3.4.2 Global Hemophilia A Market by Severity
    • 3.4.3 Global Hemophilia A Market by Treatment Type
    • 3.4.4 Global Hemophilia A Market by Treatment Regimen
    • 3.4.5 Global Hemophilia A Market Value by Treatment Regimen
    • 3.4.6 Global Hemophilia B Market Forecast by Value
    • 3.4.7 Global Hemophilia B Market by Severity
    • 3.4.8 Global Hemophilia B Market by Treatment Type
    • 3.4.9 Global Hemophilia B Market by Treatment Regimen
    • 3.4.10 Global Hemophilia B Market Value by Treatment Regimen
  • 3.5 Global Hemophilia Market by Therapy
    • 3.5.1 Global Hemophilia Replacement Therapy Market Forecast by Value
    • 3.5.2 Global Hemophilia ITI Therapy Market Forecast by Value
  • 3.6 Global Hemophilia Market by Region

4. Regional Market Analysis

  • 4.1 North America
    • 4.1.1 North America Hemophilia Market by Value
    • 4.1.2 North America Hemophilia Market Forecast by Value
    • 4.1.3 The US Hemophilia Market by Value
    • 4.1.4 The US Hemophilia Market Forecast by Value
    • 4.1.5 The US Hemophilia Market by Type
    • 4.1.6 The US Hemophilia A Market Forecast by Value
    • 4.1.7 The US Hemophilia A Treated Patient Volume Forecast
    • 4.1.8 The US Hemophilia A Severe Patients on Prophylactic Therapy
    • 4.1.9 The US Hemophilia A Severe Patients on On-Demand Therapy
    • 4.1.10 The US Hemophilia A Mild to Moderate Patients on Prophylaxis Therapy
    • 4.1.11 The US Hemophilia A Mild to Moderate Patients on On-Demand Therapy
    • 4.1.12 The US Hemophilia B Market Forecast by Value
    • 4.1.13 The US Hemophilia B Treated Patients Volume Forecast
    • 4.1.14 The US Hemophilia B Severe Patients on Prophylaxis Therapy
    • 4.1.15 The US Hemophilia B Severe Patients on On-Demand Therapy
    • 4.1.16 The US Hemophilia B Mild to Moderate Patients on Prophylaxis Therapy
    • 4.1.17 The US Hemophilia B Mild to Moderate Patients on On-Demand Therapy
  • 4.2 Europe
    • 4.2.1 Europe Hemophilia Market by Value
    • 4.2.2 Europe Hemophilia Market Forecast by Value
    • 4.2.3 Europe Hemophilia Patient Volume Forecast
    • 4.2.4 Europe Hemophilia A Patient Volume Forecast
    • 4.2.5 Europe Hemophilia B Patient Volume Forecast
  • 4.3 Asia Pacific
    • 4.3.1 Asia Pacific Hemophilia Market by Value
    • 4.3.2 Asia Pacific Hemophilia Market Forecast by Value
  • 4.4 ROW
    • 4.4.1 ROW Hemophilia Market by Value
    • 4.4.2 ROW Hemophilia Market Forecast by Value

5. Market Dynamics

  • 5.1 Growth Drivers
    • 5.1.1 Increased Focus on Prophylactic Treatment
    • 5.1.2 Increasing Diagnosis Rate
    • 5.1.3 Rise in Global Healthcare Expenditure
  • 5.2 Key Trends & Development
    • 5.2.1 Shifting Focus to Extended Half Life Therapies
    • 5.2.2 Development of Novel Hemophilia Treatments
    • 5.2.3 Popularity of Gene Therapy
  • 5.3 Challenges
    • 5.3.1 High Cost of Treatment
    • 5.3.2 Reluctance to Switch to New Therapies

6. Competitive Landscape

  • 6.1 Global Market
    • 6.1.1 Revenue Comparison - Key Players
    • 6.1.2 Market Capitalization Comparison- Key Players
    • 6.1.3 Research & Development Expenses Comparison - Key Players
    • 6.1.4 Global Hemophilia A Market Share by Company
    • 6.1.5 Global Hemophilia A Factor VIII Products Market Share by Company
    • 6.1.6 Global Hemophilia A FVIII Gene Therapy Market Share Forecast
    • 6.1.7 Global Hemophilia B Market Share by Company
    • 6.1.8 Global Hemophilia B Factor IX Products Market Share Forecast
    • 6.1.9 Global Hemophilia B Factor IX Gene Therapy Market Share Forecast
    • 6.1.10 Key Players - Major Anti-Hemophilia Products
  • 6.2 The US Market
    • 6.2.1 The US Hemophilia A Market Share by Company
  • 6.3 Europe Market
    • 6.3.1 Europe Hemophilia A Market Share by Company

7. Company Profiles

  • 7.1 Pfizer Inc.
    • 7.1.1 Business Overview
    • 7.1.2 Financial Overview
    • 7.1.3 Business Strategies
  • 7.2 Bayer Group
    • 7.2.1 Business Overview
    • 7.2.2 Financial Overview
    • 7.2.3 Business Strategies
  • 7.3 Sanofi S.A.
    • 7.3.1 Business Overview
    • 7.3.2 Financial Overview
    • 7.3.3 Business Strategies
  • 7.4 Takeda Pharmaceutical Company
    • 7.4.1 Business Overview
    • 7.4.2 Financial Overview
    • 7.4.3 Business Strategies
  • 7.5 Novo Nordisk
    • 7.5.1 Business Overview
    • 7.5.2 Financial Overview
    • 7.5.3 Business Strategies
  • 7.6 CSL Limited
    • 7.6.1 Business Overview
    • 7.6.2 Financial Overview
    • 7.6.3 Business Strategies
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.